PMID- 20558849
OWN - NLM
STAT- MEDLINE
DCOM- 20101228
LR  - 20240402
IS  - 1938-2731 (Electronic)
IS  - 1533-3175 (Print)
IS  - 1533-3175 (Linking)
VI  - 25
IP  - 6
DP  - 2010 Sep
TI  - Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted 
      living facilities.
PG  - 483-9
LID - 10.1177/1533317510372923 [doi]
AB  - The aim of this 12-week, open-label study was to determine the safety and 
      efficacy of donepezil in participants with Alzheimer's disease (AD) residing in 
      assisted living facilities (ALFs). Participants received 5 mg donepezil daily for 
      6 weeks followed by 10 mg daily for 6 weeks. Primary and secondary outcomes were 
      change from baseline in Mini-Mental State Examination (MMSE) and Neuropsychiatric 
      Inventory 8 (NPI-8) scores, respectively. Safety was assessed by adverse events 
      (AEs) and laboratory tests. Of the 97 participants, 76 completed the study. Mean 
      MMSE score (18.7 at baseline) improved 1.8 points (P < .0001) at study end. Total 
      NPI-8 score improved 1.8 points (P = .043). The most frequent AEs were nausea and 
      diarrhea. Donepezil improved cognition and behavior and was safe and well 
      tolerated. The results suggest a need for proactive screening and diagnosis of AD 
      and support the value of treatment and use of donepezil in participants residing 
      in ALFs.
FAU - Rosenblatt, Adam
AU  - Rosenblatt A
AD  - Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of 
      Medicine, Baltimore, MD 21287, USA. arosenb3@jhmi.edu
FAU - Gao, Jeff
AU  - Gao J
FAU - Mackell, Joan
AU  - Mackell J
FAU - Richardson, Sharon
AU  - Richardson S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20100617
PL  - United States
TA  - Am J Alzheimers Dis Other Demen
JT  - American journal of Alzheimer's disease and other dementias
JID - 101082834
RN  - 0 (Indans)
RN  - 0 (Nootropic Agents)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy
MH  - *Assisted Living Facilities
MH  - Cognition/*drug effects
MH  - Donepezil
MH  - Female
MH  - Humans
MH  - Indans/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Nootropic Agents/*administration & dosage/adverse effects
MH  - Piperidines/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC10845495
EDAT- 2010/06/19 06:00
MHDA- 2010/12/29 06:00
PMCR- 2010/09/01
CRDT- 2010/06/19 06:00
PHST- 2010/06/19 06:00 [entrez]
PHST- 2010/06/19 06:00 [pubmed]
PHST- 2010/12/29 06:00 [medline]
PHST- 2010/09/01 00:00 [pmc-release]
AID - 1533317510372923 [pii]
AID - 10.1177_1533317510372923 [pii]
AID - 10.1177/1533317510372923 [doi]
PST - ppublish
SO  - Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):483-9. doi: 
      10.1177/1533317510372923. Epub 2010 Jun 17.